Key Takeaways
- • Blackstone and TPG to acquire Hologic for $18.3 billion enterprise value ($76 per share in cash plus up to $3 per share in contingent value rights), representing the largest medical devices deal in almost two decades.
- • Hologic shareholders receive $76 per share in immediate cash consideration plus a non-tradable contingent value right (CVR) of up to $3 per share, payable in two tranches upon achievement of specific global revenue milestones for the Breast Health business in fiscal years 2026 and 2027.
- • The transaction represents a 46% premium to Hologic's closing price on May 23, 2025, the last full trading day prior to media reports of the possible transaction.
- • Valuation of approximately 14.1x EBITDA reflects a significant take-private by two of the world's largest alternative asset managers; transaction includes minority investments from Abu Dhabi Investment Authority (ADIA) and GIC.
- • Strategic rationale centers on strengthening Hologic's leadership position in women's health, accelerating growth through operational scaling, and leveraging private equity resources for innovation and capital deployment.
Summary
Blackstone and TPG announced on October 21, 2025, a definitive agreement to acquire Hologic Inc. in an all-cash transaction valued at up to $18.3 billion on an enterprise value basis, marking the largest medical devices deal in nearly two decades. Under the agreement terms, Hologic shareholders will receive $76 per share in cash at closing, with an additional non-tradable contingent value right (CVR) providing up to $3 per share in two equal tranches of $1.50 each, contingent upon the achievement of specified global revenue targets for Hologic's Breast Health business segment in fiscal years 2026 and 2027.
The transaction represents a substantial 46% premium to Hologic's closing stock price of approximately $52 per share on May 23, 2025, the last full trading day prior to initial media reports of a potential transaction. The aggregate consideration of up to $79 per share reflects a valuation of approximately 14.1x EBITDA, consistent with recent large-cap medtech take-private transactions in the sector. The deal structure, incorporating earnout-style CVR payments tied to specific business performance metrics, aligns acquisition economics with operational execution during the critical fiscal years 2026 and 2027.
The transaction includes significant minority equity investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) and an affiliate of the Government of Singapore Investment Corporation (GIC), providing additional financial flexibility and global strategic perspectives alongside the two lead sponsors. This multi-sponsor structure is characteristic of mega-deals within the private equity medtech space, distributing capital requirements and risk across institutional investors with substantial dry powder and sector expertise.
According to deal rationale disclosed by the parties, the acquisition is positioned to strengthen Hologic's competitive leadership in women's health diagnostics and imaging, while providing enhanced resources for innovation investment, operational scaling, and international expansion initiatives. The private equity sponsors indicate the transaction will enable the organization to pursue strategic objectives unconstrained by public market cycles and investor expectations for near-term earnings accretion. The transaction is expected to close subject to customary closing conditions and regulatory approvals.
The transaction represents a substantial 46% premium to Hologic's closing stock price of approximately $52 per share on May 23, 2025, the last full trading day prior to initial media reports of a potential transaction. The aggregate consideration of up to $79 per share reflects a valuation of approximately 14.1x EBITDA, consistent with recent large-cap medtech take-private transactions in the sector. The deal structure, incorporating earnout-style CVR payments tied to specific business performance metrics, aligns acquisition economics with operational execution during the critical fiscal years 2026 and 2027.
The transaction includes significant minority equity investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) and an affiliate of the Government of Singapore Investment Corporation (GIC), providing additional financial flexibility and global strategic perspectives alongside the two lead sponsors. This multi-sponsor structure is characteristic of mega-deals within the private equity medtech space, distributing capital requirements and risk across institutional investors with substantial dry powder and sector expertise.
According to deal rationale disclosed by the parties, the acquisition is positioned to strengthen Hologic's competitive leadership in women's health diagnostics and imaging, while providing enhanced resources for innovation investment, operational scaling, and international expansion initiatives. The private equity sponsors indicate the transaction will enable the organization to pursue strategic objectives unconstrained by public market cycles and investor expectations for near-term earnings accretion. The transaction is expected to close subject to customary closing conditions and regulatory approvals.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.